Мероприятия

Баннер
 

Морфоклинические варианты аденом гипофиза, секретирующих гормон роста. особенности диагностики и лечения
Автор: В. Пронин, М. Анциферов, Ю. Потешкин   

 

magazine-vrach-2013-10-005

Морфоклинические варианты аденом гипофиза, секретирующих гормон роста. особенности диагностики и лечения

Обсуждается необходимость дифференцированного подхода к лечению больных с секретирующими гормон роста аденомами гипофиза с учетом существующего разнообразия патоморфологических и клинических вариантов течения заболевания, а также разработки его диагностических и прогностических маркеров.
Morphoclinical variants of growth hormone- secreting pituitary adenomas. specific features of diagnosis and treatment
The paper discusses whether it is necessary to apply a differential approach to treating patients with growth hormone-secreting pituitary adenomas in terms of the existing variety of pathomorphological and clinical variants of the course of disease, as well as the development of its diagnostic and prognostic markers.The paper discusses whether it is necessary to apply a differential approach to treating patients with growth hormone-secreting pituitary adenomas in terms of the existing variety of pathomorphological and clinical variants of the course of disease, as well as the development of its diagnostic and prognostic markers.
Литература
1. Kontogeorgos G. Classification and Pathology of Pituitary Tumors // Endocrine. – 2005; 28 (1):27–35.
2. Melmed S. Mechanisms for pituitary tumorigenesis: the plastic pituitary // J. Clin. Invest. – 2003; 112: 1603–18.
3. Li J., Stefaneanu L., Kovacs K. et al. Growth hormone (GH) and prolactin (PRL) gene expression and immunoreactivity in GH- and PRL-producing human pituitary adenomas // Virchov. Arch. A. Pathol. Anat. Histopathol. – 1993; 422 (3): 193–201.
4. Kato M., Inochita N., Sugiyama T. et al. Differential expression of genes related to drug responsivenes between sparsely and densely granulated somatotroph adenomas // Endocrin. J. – 2012; 59 (3): 221–8.
5. Horvath E., Kovacs K. Pathology of Acromegaly // Neuroendocrinology. – 2006; 83: 161–5.
6. Obary A., Sano T., Ohyama K. et al. Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form // Endocr. Pathol. – 2008; 19 (2): 82–91.
7. Wang M., Mou C., Jiang M. The characteristics of acromegalic patients with hyperprolactinemia and the differences in patients with merely GH-secreting adenomas: clinical analysis of 279 cases // Eur. J. Endocrinol. – 2012; 166 (5): 797–802.
8. Pawlikowski M., Kunert-Radek J., Radek M. Plurihormonality of pituitary adenomas in light of immunohistochemical studies // Endokrynol. Polska. – 2010; 61 (1): 63–6.
9. Saeger W., Ludecke D., Buchfelder M. et al. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry // Eur. J. Endocrinol. – 2007; 156: 203–16.
10. Besser G., Burman P., Daly A. Predictors and rates of treatment-resistant tumor growth in acromegaly // Eur. J. Endocrinol. – 2005; 153 (2): 187–93.
11. Petersenn S., Buchfelder M., Gerbert B. еt al. Age and sex as predictors of biochemical activity in acromegaly: analysis of 1485 patients from the German Acromegaly Register // Clin. Endocrinol. (Oxf.). – 2009; 71 (3): 400–5.
12. Tanimoto K., Hizuka N., Fukuda I. et al The influence of age on the GH–IGF1 axis in patients with acromegaly // Eur. J. Endocrinol. – 2008; 159 (4): 375–9.
13. Bhansali A., Upreti V., Dutta P. et al Adolescent acromegaly: clinical parameters and treatment outcome // J. Pediatr. Endocrinol. Metab. – 2010; 23 (10): 1047–54.
14. Мельниченко Г.А., Пронин В.С., Колода Д.Е. и др. Место аналогов соматостатина в комбинированном лечении синдрома избыточной продукции гормона роста. Учебно-метод. пособ, 2008; 120 с.
15. Bronstein M. Acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome // Front Horm. Res. – 2006; 35: 129–34.
16. Takei M., Suzuki M., Kajiva H. et al. Immunohistochemical detection of Somatostatin Receptor (SSTR) Subtypes 2A and 5 in Pituitary Adenoma from Acromegalic Patients: Good Correlation with Preoperative Response to Octreotide // Endocrin. Pathol. – 2007; 18 (4): 208–16.
17. Taboada G., Luque R., Neto L. et al. Quantitative analysis of somatostatin receptor subtypes (1–5) gene exp ression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR // Eur. J. Endocrinol. – 2008; 158 (3): 295–303.
18. Fougner S., Bogota O., Berg J. et al. The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma // Clin. Endocrinol. (Oxf.). – 2008; 68: 458–65.
19. Ezzat S., Kontogeorgos G., Redelmeier D. et al. In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide // Eur. J. Endocrinol. – 1995; 133: 686–90.
20. Kasuki L., Wildemberg L., Neto L. et al. Ki-67 is predictor of acromegaly control with octreotide LAR independent of SSTR2 status and rekates to cytokeratin pattern // Eur. J. Endocrinol. – 2013; 169 (2): 217–23.
21. Pisarek H., Pawlikowski M., Kunert-Radek J. et al. Expression of somatostatin receptor subtypes in human pituitary adenomas – immunohistochemical studies // Endocrinol. Pol. – 2009; 60 (4): 240–51.
22. Plöckinger U., Albrecht S., Mawrin C. et al. Selective Loss of Somatostatin Receptor 2 in Octreotide-Resistant Growth Hormone-Secreting Adenomas // J. Clin. Endocrinol. Metab. – 2008; 93 (4): 1203–10.
23. Kiseljak-Vassiliades K., Snaf S., Kerr J. et al. Clinical implications of growth hormone-secreting tumor subtypes // Endocrine. – 2012; 42 (1): 18–28.
24. Puig-Domingo M., Resmini E., Gomez-Anson B. et al. Magnetic resonance imaging as a predictor of response to somatostatin analog in acromegaly after surgical failure // J. Clin. Endocrinol. Metab. – 2010; 95 (11): 4973–8.
25. Astruc B. et al. Long-Acting Octreotide and Prolonged-Release Lanreotide Formulations Have Different Pharmacokinetic Profiles // J. Clin. Pharmacol. – 2005; 45: 836–44.
26. Sowinski J., Sawicka N., Piatek K. et al. Pharmacoeconomic aspects of the treatment of pituitary gland tumours // Contemp. Oncol. (Pozn). – 2013; 17 (2): 137–43.

 

 

 
Рассылка
Важно

→ Фармакопейные статьи


→ Медицинские архивы на службе современного врача


→ Перечень медицинских технологий

ЭКД архив

 

Баннер
Баннер
Баннер
Информационные партнеры:
Баннер
Баннер
Баннер
Баннер
Баннер
Баннер
Баннер
Баннер
Баннер
Баннер
Баннер
Баннер